Results 11 to 20 of about 721 (165)

Early therapeutic drug monitoring of methotrexate and its association with acute kidney injury: A retrospective cohort study [PDF]

Cancer Medicine
Introduction High‐dose methotrexate (HDMTX) use can be limited by the development of acute kidney injury (AKI). Early AKI detection is paramount to prevent further renal injury and irreversible toxicities.
Nicolás Tentoni, Miriam Hwang, Gabriela Villanueva, Ryan Combs, Jennifer Lowe, Laura B. Ramsey, Zachary L. Taylor, Thais Murciano Carrillo, María Dolores Aumente, Teresa López‐Viñau López, Carmelo Rizzari, Scott C. Howard   +11 more
doaj   +5 more sources

A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK [PDF]

Health Science Reports
Introduction High‐dose methotrexate (HDMTX) is administered for the treatment of some malignancies. Serious complications after the administration of HDMTX are rare, but occasionally MTX may precipitate in the renal tubes causing a delayed elimination ...
Stefan Bielack, Christopher P. Fox, Khê Hoang‐Xuan, Ariadna Giró‐Perafita, Carmelo Rizzari   +4 more
doaj   +5 more sources

Strategies for Managing Toxicities With High‐Dose Methotrexate in Haematological Malignancies: Lessons From Clinical Cases [PDF]

Clinical Case Reports
High‐dose methotrexate (HDMTX) is a key component of induction therapy for a range of cancers, but can lead to serious adverse effects, including acute kidney injury (AKI). We report two cases of HDMTX use in haematological malignancies. Patient 1 was an
Vanessa McLelland, Martin Guscott, Matthew R. Wilson   +2 more
doaj   +3 more sources

A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment [PDF]

Journal of Cancer Research and Clinical Oncology
High-dose methotrexate (HDMTX) is used in the treatment of a range of adult and childhood cancers. Although HDMTX can provide effective anti-tumor activity with an acceptable safety profile for most patients, delayed methotrexate elimination (DME ...
Stefan S. Bielack, Carole Soussain, Christopher P. Fox, Caroline Houillier, Thais Murciano, Wendy Osborne, Pier Luigi Zinzani, Carmelo Rizzari, Stefan Schwartz   +8 more
doaj   +7 more sources

Production of “biobetter” variants of glucarpidase with enhanced enzyme activity [PDF]

Biomedicine and Pharmacotherapy, 2019
Glucarpidase, also known as carboxypeptidase G2, is a Food and Drug Administration-approved enzyme used in targeted cancer strategies such as antibody-directed enzyme prodrug therapy (ADEPT). It is also used in drug detoxification when cancer patients have excessive levels of the anti-cancer agent methotrexate.
Atilio Reyes Romero, Alex Domling, Sayed K Goda   +2 more
exaly   +5 more sources

Navigating methotrexate toxicity: Examining the therapeutic roles of folinic acid and glucarpidase. [PDF]

Br J Clin Pharmacol
Methotrexate (MTX) toxicity varies depending on factors such as dosing frequency (acute or repeated), dosage (low or high) and the administration route (oral, parenteral or intrathecal). Renal impairment can trigger or exacerbate MTX toxicity. Acute oral low‐dose MTX (LDMTX) overdoses seldom lead to toxicity due to the saturable maximal bioavailable ...
Chan BS, Bosco AA, Buckley NA.
europepmc   +4 more sources

Case Report: Effective methotrexate removal by combined hemodialysis and polymeric resin hemoadsorption [PDF]

Frontiers in Nephrology
BackgroundHigh-dose methotrexate (HDMTX) is central to treating primary central nervous system lymphoma but carries a risk of acute kidney injury (AKI), which can delay methotrexate (MTX) clearance and increase toxicity.
Maria Rita Dias, Carla Nicolau, Hugo Ferreira, Sérgio Chacim, Isabel Oliveira, Gonçalo de Câmara Negalha, José Mário Mariz, José Maximino Costa   +7 more
doaj   +5 more sources

Isolation and molecular characterization of novel glucarpidases: Enzymes to improve the antibody directed enzyme pro-drug therapy for cancer treatment. [PDF]

PLoS ONE, 2018
Repeated cycles of antibody-directed enzyme pro-drug therapy (ADEPT) and the use of glucarpidase in the detoxification of cytotoxic methotrexate (MTX) are highly desirable during cancer therapy but are hampered by the induced human antibody response to ...
Fatma B Rashidi, Alanod D AlQhatani, Sara S Bashraheel, Shabnam Shaabani, Matthew R Groves, Alexander Dömling, Sayed K Goda   +6 more
doaj   +7 more sources

Methotrexate induced hepatotoxicity in metabolic dysfunction-associated steatotic liver disease. [PDF]

JPGN Rep
Hepatotoxicity is an under-recognized and potentially fatal side effect of high-dose methotrexate (HDMTX) chemotherapy, and this risk is compounded in children with metabolic dysfunction-associated steatotic liver disease and/or metabolic-associated ...
Berkemeyer A, Wagner E, Hashmat S, Azzam RK.   +3 more
europepmc   +4 more sources

Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org

Clinical and Translational Science, 2023
The MTXPK.org webtool was launched in December 2019 and was developed to facilitate model‐informed supportive care and optimal use of glucarpidase following the administration of high‐dose methotrexate (HDMTX).
Zachary L. Taylor, Tamara P. Miller, Ethan A. Poweleit, Nicholas P. DeGroote, Lauren Pommert, Oluwafunbi Awoniyi, Sarah G. Board, Ngozi Ugboh, Vivek Joshi, Nick Ambrosino, Ashley Chavana, Melanie B. Bernhardt, Eric S. Schafer, Maureen M. O'Brien, Sharon M. Castellino, Laura B. Ramsey   +15 more
doaj   +2 more sources